Ensho Therapeutics has presented additional data supporting NSHO-101, also referred to as EA1080, as an oral one-time-a-day ...

The Business Research Company Updated 2025 Market Reports Released: Trends, Forecasts to 2034 – Early Purchase Your Competitive Edge Today!

Eisai announces Leqembi sales reaches €200 million; BioArctic to receive €10 million payment: Stockholm, Sweden Wednesday, February 19, 2025, 14:00 Hrs [IST] BioArctic AB’s ...

At the State of Black Health second annual summit hosted by BlackDoctor.org in partnership with USA TODAY, corporate leaders ...

Allarity expects to pursue multiple advantaged regulatory pathways to expedite approval in the first half of 2025. Allarity ...

Two widely touted Alzheimer’s drugs have been shown to enable patients to remain in their homes for longer periods of time.

A high omega-3, low omega-6 diet with fish oil led to a significant reduction in a biomarker for prostate cancer progression ...

"We are now, within short, ready to initiate the phase 2b study - with the goal of making fostrox + Lenvima the first approved medical treatment for second-line liver cancer" October - DecemberFinanci ...

Additional data from CheckMate 274 showed that adjuvant nivolumab benefits patients with muscle-invasive bladder cancer with ...

Q2 2025 Earnings Conference Call February 19, 2025 5:00 PM ET. Company Participants. Brad O'Connor - Chief Executive Officer Darren Watson - Chief F ...

Brad O'Connor, CEO, highlighted the company’s record revenue of $23.9 million for the first half of FY 2025, driven by a 27% growth in clinical trials revenue compared to the prior corresponding ...

Eisai has been steadily building up expertise in the use of digital health systems to support people with dementia but has now gone one step further – launching a dedicated subsidiary company to ...